Cervarix Gets One Up On Gardasil In Cross-Protection: HPV-31 In FDA Approval
Executive Summary
GlaxoSmithKline's effort to make its bivalent human papillomavirus vaccine, Cervarix, into a multivalent product through proof of cross protection against additional HPV virus strains achieved a partial, one-virus, success at FDA